Evidence map›Paper›PMID 40406388›Full record

ArticleMaternal-fetal medicine (Wolters Kluwer Health, Inc.)2023

Maternal and Perinatal Outcomes of SARS-CoV-2 and Variants in Pregnancy.

Qiaoli Feng, Qianwen Cui, Zhansong Xiao, Zengyou Liu, Shangrong Fan

Abstract read
In one paragraph

Article in Maternal-fetal medicine (Wolters Kluwer Health, Inc.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qiaoli FengDepartment of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Qianwen CuiDepartment of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Zhansong XiaoDepartment of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen 518036, China.
Zengyou LiuDepartment of Obstetrics and Gynecology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518052, China.
Shangrong FanDepartment of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen 518036, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pregnancy is a physiological state that predisposes women to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a disease that can cause adverse maternal and perinatal outcomes. The severity of coronavirus disease 2019 (COVID-19) disease is known to vary by viral strain; however, evidence for the effects of this virus in pregnant women has yet to be fully elucidated. In this review, we describe maternal and perinatal outcomes, vaccination, and vertical transmission, among pregnant women infected with the different SARS-CoV-2 variants identified to date. We also summarize existing evidence for maternal and perinatal outcomes in pregnant women with specific information relating to SARS-CoV-2 variants. Our analysis showed that Omicron infection was associated with fewer severe maternal and perinatal adverse outcomes while the Delta variant was associated with worse pregnancy outcomes. Maternal deaths arising from COVID-19 were found to be rare (<1.0%), irrespective of whether the virus was a wild-type strain or a variant. Severe maternal morbidity was more frequent for the Delta variant (10.3%), followed by the Alpha (4.7%), wild-type (4.5%), and Omicron (2.9%) variants. The rates of stillbirth were 0.8%, 4.1%, 3.1%, and 2.3%, respectively, in pregnancies infected with the wild-type strain, Alpha, Delta, and Omicron variants, respectively. Preterm birth and admission to neonatal intensive care units were more common for cases with the Delta infection (19.0% and 18.62%, respectively), while risks were similar for those infected with the wild-type (14.7% and 11.2%, respectively), Alpha (14.9% and 13.1%), and Omicron variants (13.2% and 13.8%, respectively). As COVID-19 remains a global pandemic, and new SARS-CoV-2 variants continue to emerge, research relating to the specific impact of new variants on pregnant women needs to be expanded.

Indexed as

AlphaCOVID-19DeltaOmicronPregnancy outcomesSARS-CoV-2Variants

Identifiers

PMID40406388
PMCPMC12094409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.